TSLP and asthma: With regards to anti-TSPL tezepelumab, it is important to know that despite the fact that tezepelumab is the first biologic agent with at least some degree of activity in T2 low refractory severe asthma, which remains an unmet need, results from randomized controlled clinical trials suggest that blocking the upstream alarmin TSLP with tezepelumab results in clinically meaningful improvements in asthma control in patients with T2 high asthma.